Retatrutide — Triple Receptor Agonist

Background

Retatrutide (developmental code LY3437943) is an investigational triple agonist developed by Eli Lilly that simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. It is the first 'triple G' agonist to reach late-stage clinical trials.

Mechanism

GLP-1 and GIP receptor activation drive glucose-dependent insulin secretion, slowed gastric emptying, and central appetite suppression. The added glucagon receptor activity is hypothesised to increase energy expenditure and hepatic fat clearance — properties not delivered by GLP-1-only or GLP-1/GIP dual agonists.

What is proven

Phase 2 data published in the New England Journal of Medicine (Jastreboff et al., 2023) reported mean body-weight reductions of approximately 24.2% at 48 weeks at the highest 12 mg weekly dose, in adults with obesity without type 2 diabetes — exceeding any previously published metabolic agent. Concurrent improvements in waist circumference, blood pressure, and lipid profile were reported.

Parallel Phase 2 data in adults with type 2 diabetes (Rosenstock et al., NEJM 2023) showed HbA1c reductions and substantial weight loss across the dose range.

Pre-clinical and Phase 2 imaging data show significant hepatic fat reduction in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD).

What is NOT proven (yet)

Phase 3 trials (the TRIUMPH program) are ongoing; as of the publication date of this article, no regulatory approval has been granted for Retatrutide anywhere in the world. Long-term cardiovascular outcomes, lean-mass preservation, and durability of weight loss beyond two years are not yet established.

Discontinuation effects (rate of weight regain after stopping) have not been published in detail.

Open research questions

Whether the glucagon receptor activity preserves lean mass and energy expenditure long-term, the cardiovascular outcomes signal (CV outcome trials are required for any obesity drug expected to be used chronically), and the metabolic and bone-density profile of the >20% weight-loss tier.

Regulatory status

Not approved by any regulator as of mid-2026. Phase 3 TRIUMPH program ongoing.

All Proteus® compounds are sold strictly for in-vitro research. Nothing on this page is medical advice, a treatment claim, or a recommendation for human use. Where compounds are licensed medicines in any jurisdiction, that approval applies to the licensed product supplied through a regulated pharmacy — not to research-grade material.